Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema.[1] It is a plasma kallikrein inhibitor.[2]
Clinical data | |
---|---|
Other names | KVD-900 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H26FN5O4 |
Molar mass | 491.523 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Sebetralstat - KalVista Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, et al. (October 2022). "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema". Journal of Medicinal Chemistry. 65 (20): 13629–13644. doi:10.1021/acs.jmedchem.2c00921. PMC 9620001. PMID 36251573.